BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 9, 2011
View Archived Issues
Studies provide insight into TL-32711 activity and dosing
Read More
Phase I trial of Antisense Therapeutics product meets endpoint
Read More
Sanofi reports data from GetGoal Duo 1 study
Read More
Primary endpoint met in Toviaz trial
Read More
International team identifies potential therapeutic for cocaine addiction
Read More
Translational profiling of serotonergic neurons reveals new gene linked to autism
Read More
Phase II studies evaluate K-134 in peripheral arterial disease
Read More
New diacylglycerol O-acyltransferase 1 inhibitors show potential to treat obesity and/or diabetes
Read More
New inhibitors of fatty acid synthase presented
Read More
U.S. university extracts novel agents with antidiabetic potential from African shrub
Read More
Vertex Pharmaceuticals patents novel voltage-gated sodium channel antagonists
Read More
Novel immunomodulating and anti-inflammatory compounds described
Read More
BioLineRx reports final data from phase Ia BL-1021 trial
Read More
Horizon Pharma launches new combination tablet for rheumatoid arthritis and osteoarthritis
Read More
Novel GPR119 receptor agonists disclosed by Boehringer Ingelheim
Read More
TetraLogic Pharmaceuticals begins new phase I/II TL-32711 trial
Read More
Bristol-Myers Squibb divulges new potential therapeutics for hepatitis C
Read More
DM-199 increases C-peptide levels in animal model
Read More
Morphotek terminates phase III farletuzumab trial
Read More
Cyclacel Pharmaceuticals reports interim data from sapacitabine trials
Read More
Aradigm obtains U.S. patent for Pulmaquin and plans phase III development
Read More
Ono Pharmaceutical announces new launch in Japan
Read More
European Commission approves Takeda product for essential hypertension
Read More
Theratechnologies discontinues tesamorelin COPD program
Read More
ChemoCentryx begins new study of CCX-140 in diabetic nephropathy
Read More
FDA committee votes in favor of peginesatide
Read More